Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability, and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults.

Trial Profile

Randomized, Double Blind, Controlled Phase I Trial of the Safety, Tolerability, and Immunogenicity of Graded Doses of XRX-001 Yellow Fever 17D, Inactivated Vaccine, Alum Adsorbed in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2016

At a glance

  • Drugs Yellow fever vaccine (Primary)
  • Indications Yellow fever
  • Focus Adverse reactions
  • Sponsors Xcellerex
  • Most Recent Events

    • 26 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Apr 2011 Results published in the New England Journal of Medicine.
    • 07 Apr 2011 Results have been published in the New England Journal of Medicine, according to an Xcellerex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top